Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong overseas demand for weight-loss and ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

The social-media company said it would “aggressively” raise spending to stay competitive in the artificial-intelligence arms ...

Eli Lilly chairman and CEO David Ricks joins CNBC’s “Squawk on the Street” team to discuss its quarterly earnings report that ...

This week's dividend activity included increased payouts from Visa ( V) and Marathon Petroleum ( MRC) as well as declarations ...

On Wednesday, Lilly said Zepbound would be sold directly in Walmart pharmacies for $349 to $499 a month. Next year, Lilly is ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...

Patients will be able to access Eli Lilly's weight loss drug Zepbound at Walmart pharmacies nationwide through its ...